Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Roshini Claire Anthony, 2 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Folic acid treatment may halt disease progression in mild-to-moderate CKD

28 Mar 2020

Patients with mild-to-moderate chronic kidney disease (CKD) may benefit from folic acid treatment, which helps reduce the likelihood of CKD progression, especially among those with high vitamin B12 levels, as shown in a study.

Researchers conducted a posthoc analysis of 1,374 hypertensive adults with mild-to-moderate CKD and vitamin B12 measurements at baseline from the kidney disease substudy of the China Stroke Primary Prevention Trial (CSPPT), conducted in 20 communities in Jiangsu province, a region with low folate consumption.

Patients were randomized to receive enalapril 10 mg alone or in combination with folic acid 0.8 mg. Mean baseline estimated glomerular filtration rate (eGFR) of the population was 86.1 mL/min/1.73 m2. Median treatment duration was 4.4 years.

The primary outcome of CKD progression was less likely to occur with enalapril–folic acid treatment than with enalapril alone among patients with higher baseline vitamin B12 levels (≥248 pmol/L; odds ratio [OR], 0.17, 95 percent confidence interval [CI], 0.07–0.40). This difference was not observed among patients with lower baseline B12 levels (<248 pmol/L or metabolic B12 deficiency; OR, 1.21, 95 percent CI, 0.51–2.85).

The interaction between vitamin B12 level and folic acid treatment was significant (p=0.001).

Progression was defined as a decrease in eGFR of ≥30 percent and to a level of <60 mL/min/1.73 m2 if baseline eGFR was ≥60 mL/min/1.73 m2; or a decrease in eGFR of ≥50 percent if baseline eGFR was <60 mL/min/1.73 m2; or kidney failure.

Researchers acknowledged several limitations to the study, including the analysis being posthoc in nature and the event rate being low.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Roshini Claire Anthony, 2 days ago

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.